📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-05 22:51
1 analysed today
FollowTelegram
1
Today
151,445
All-time analysed
43,380
Positive
6,733
Negative
92,520
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
NCLT Chennai Sanctions Scheme of Amalgamation of Dr. Agarwal's Eye Hospital into AHCL
The Hon'ble NCLT Chennai bench has sanctioned the Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited (AEHL) into Dr. Agarwal's Health Care Limited (AHCL). The order was pronounced on September 30, 2026, and uploaded on October 05, 2026. The scheme will have an Appointed Date of April 01, 2026, and will become operative upon completion of conditions in Clause 24. With AEHL having a market cap of ₹2,523 crore and TTM revenue of ₹497 crore, this amalgamation will consolidate the hospital business into the parent entity.
Confidence: HIGH
What changedNCLT has approved the merger of listed Dr. Agarwal's Eye Hospital Limited into Dr. Agarwal's Health Care Limited.
Why it mattersThe corporate restructuring will result in the amalgamation of AEHL (₹2,523 Cr market cap) into AHCL, leading to share allotment per the swap ratio and potential delisting/listing changes.
Appointed Date: April 01, 2026Order pronouncement date: September 30, 2026Order upload date: October 05, 2026Current Market Cap: ₹2,523 Cr
📅 Short termReceipt of the certified order and filing with the Registrar of Companies will establish the effective date and subsequent announcement of the record date for share exchange.
📈 Long termConsolidates Dr. Agarwal's clinical eye care operations with the healthcare parent entity, streamlining corporate architecture and operations.
⚠ Risk flags
- Share swap execution and regulatory filings completion timelines pending
Key Highlights
NCLT Chennai sanctioned the amalgamation of AEHL into AHCL in order pronounced on September 30, 2026
Sanction order officially uploaded on the NCLT website on October 05, 2026
Appointed Date of the scheme is confirmed as opening of business on April 01, 2026
Effective Date will be the first day of the calendar month following completion of Clause 24 conditions
👀 What to Watch
Track the announcement of the certified order copy, completion of Clause 24 conditionalities, the fixation of the Record Date, and the final Share Exchange Ratio details.
Dr Agarwals Eye Hospital Q1 FY27: Revenue up 22% to ₹143 Cr, PAT up 35% to ₹23 Cr
Dr Agarwals Eye Hospital reported a strong performance for Q1 FY27, with revenue from operations growing 22.3% YoY to ₹142.97 Cr. Net profit surged 35.5% YoY to ₹23.38 Cr, supported by healthy EBITDA margins of 31.6%. The company has utilized ₹28.20 Cr of the ₹70 Cr raised via preferential allotment in late 2025 for its stated objectives, with the balance currently in debt mutual funds. Additionally, the board re-appointed M/s. B Y & Associates as Cost Auditors for FY 2026-27.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27 showing strong double-digit growth and confirmed the re-appointment of its cost auditors.
Why it mattersThe results demonstrate strong organic growth in the eye care segment and efficient management of operational costs, while the capital raise utilization indicates ongoing expansion activities.
Revenue (Q1 FY27): ₹142.97 CrNet Profit (Q1 FY27): ₹23.38 CrYoY Revenue Growth: 22.3%EBITDA Margin: 31.6%Preferential Issue Utilization: ₹28.20 Cr
📅 Short termThe stock is likely to react positively to the strong earnings growth and margin expansion reported for the June quarter.
📈 Long termThe company's ability to scale its specialized hospital model while maintaining high ROCE (17%) and utilizing fresh capital for expansion remains the key long-term driver.
⚠ Risk flags
- High Debt-to-Equity ratio of 0.94
- Rising consultancy charges for doctors (up 27% YoY)
Key Highlights
Revenue from operations increased 22.3% YoY to ₹142.97 Cr from ₹116.92 Cr
Net profit after tax grew 35.5% YoY to ₹23.38 Cr compared to ₹17.26 Cr
EBITDA for the quarter stood at ₹45.22 Cr, up 19.2% from ₹37.93 Cr in the previous year
Basic EPS improved significantly to ₹48.38 from ₹36.72 in the year-ago period
Company utilized ₹28.20 Cr out of ₹70 Cr raised through preferential issue as of June 30, 2026
👀 What to Watch
Investors should monitor the deployment of the remaining ₹41.8 Cr from the preferential issue into new hospital capacity and track if the company can maintain its 30%+ operating margins amidst rising employee and consultancy costs.
35% PAT Growth to ₹23.38 Cr in Q1 FY27; Revenue Up 22% YoY
Dr Agarwals Eye Hospital reported a strong start to FY27 with revenue from operations growing 22.3% YoY to ₹142.97 Cr. Net profit for the quarter increased 35.5% YoY to ₹23.38 Cr, significantly outperforming the ₹17.26 Cr reported in Q1 FY26. EBITDA margins remained robust at 31.6%, although slightly lower than the 32.4% in the year-ago period. The company also reported that ₹28.20 Cr of the ₹70 Cr raised via preferential issue in late 2025 has been utilized, with the balance held in debt mutual funds.
Confidence: HIGH
What changedThe company has demonstrated strong sequential and year-on-year growth in both top-line and bottom-line performance for the first quarter of the new financial year.
Why it mattersThe results confirm the company's ability to scale its eye care services profitably, maintaining high margins while growing revenue at a 20%+ clip, which is significant for a mid-cap hospital chain.
Revenue (Q1 FY27): ₹142.97 CrNet Profit (Q1 FY27): ₹23.38 CrYoY Revenue Growth: 22.3%YoY PAT Growth: 35.5%EBITDA Margin: 31.6%Preferential Funds Unutilized: ₹41.80 Cr
📅 Short termThe strong earnings beat, particularly on the profit front, is likely to be viewed positively by the market in the coming weeks.
📈 Long termThe company's consistent ability to generate 30%+ OPM and its cash-rich position for expansion suggest a healthy long-term growth trajectory in the specialized healthcare space.
⚠ Risk flags
- Slight YoY compression in EBITDA margins
- Concentration in specialized eye care services
Key Highlights
Revenue from operations increased 22.3% YoY to ₹142.97 Cr from ₹116.92 Cr.
Net profit after tax rose 35.5% YoY to ₹23.38 Cr compared to ₹17.26 Cr in Q1 FY26.
EBITDA for the quarter stood at ₹45.22 Cr, representing a 31.6% margin.
Basic and Diluted EPS improved to ₹48.38 from ₹36.72 in the corresponding quarter last year.
₹28.20 Cr of the ₹70 Cr preferential allotment proceeds have been utilized as of June 30, 2026.
👀 What to Watch
Investors should monitor the deployment of the remaining ₹41.8 Cr in preferential issue proceeds for potential network expansion and observe if the company can maintain its 30%+ operating margins amidst rising consultancy and employee costs.
Dr Agarwals Q1 FY27: Net Profit up 35.5% YoY to ₹23.38 Cr; Revenue grows 22.3%
Dr Agarwals Eye Hospital reported a strong start to FY27 with Q1 revenue from operations growing 22.3% YoY to ₹142.97 Cr. Net profit surged 35.5% YoY to ₹23.38 Cr, significantly outpacing revenue growth due to operational leverage. EBITDA for the quarter stood at ₹45.22 Cr, a 19.2% increase from ₹37.93 Cr in the previous year. The company also reported that it has utilized ₹28.20 Cr of the ₹70 Cr raised via preferential issue in September 2025, with the balance currently held in debt mutual funds.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing a significant acceleration in both top-line and bottom-line growth compared to the previous year.
Why it mattersThe strong earnings growth validates the company's scaling strategy in the specialized eye care market and shows efficient utilization of capital raised in late 2025.
Q1 Revenue from Operations: ₹142.97 CrQ1 Net Profit: ₹23.38 CrYoY Revenue Growth: 22.3%YoY PAT Growth: 35.5%Q1 Revenue vs TTM Revenue: 30.3%Preferential Funds Utilized: ₹28.20 Cr
📅 Short termThe stock is likely to react positively to the strong double-digit growth in PAT and healthy EBITDA margins reported for the quarter.
📈 Long termThe company's ability to maintain high margins while deploying capital for expansion will be critical for long-term value creation in the competitive hospital sector.
⚠ Risk flags
- High Debt-to-Equity ratio of 0.94
- Concentration risk in a single medical specialty
Key Highlights
Revenue from operations increased 22.3% YoY to ₹142.97 Cr from ₹116.92 Cr.
Net Profit after tax grew 35.5% YoY to ₹23.38 Cr compared to ₹17.26 Cr in Q1 FY26.
EBITDA reached ₹45.22 Cr for the quarter, up from ₹37.93 Cr in the year-ago period.
Basic and Diluted EPS rose to ₹48.38 from ₹36.72 in the corresponding quarter last year.
Utilized ₹28.20 Cr of the ₹70 Cr preferential allotment proceeds as of June 30, 2026.
👀 What to Watch
Watch for the deployment timeline of the remaining ₹41.8 Cr preferential issue proceeds and whether the current 31.6% EBITDA margin is sustainable as the company expands.
